EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of chemotherapy on breast cancer−related lymphedema: a retrospective study

Liqin Wang, Yuemin Weng, Weiqi Wei, Jun Bu, Cici Zhang

Frontiers in Oncology · 27.04.2026 · 16

DOI: 10.3389/fonc.2026.1787021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 27.04.2026. Verfasst von Liqin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center (Preventive Treatment) of Baiyun Hospital, Guangdong Provincial Second Hospital of Traditional Chinese Medicine (Guangdong P…. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to investigate the impact of chemotherapy on the risk of breast cancer-related lymphedema (BCRL), with a specific focus on effects of different regimens, treatment duration (number of cycles), and timing of chemotherapy.

Methods

In this retrospective study, 201 patients with pathologically confirmed breast cancer who underwent surgical treatment at Guangzhou Red Cross Hospital between January 1, 2020, and December2023, 2023 were enrolled. Group differences in BCRL incidence were analyzed using the chi-square test. Univariate logistic regression was used to identify factors associated with BCRL.

Results

BCRL occurred in 31 patients (15.4%). Univariate analysis revealed that tumor stage, axillary lymph node dissection, sentinel lymph node biopsy, chemotherapy, and regional nodal irradiation were significantly associated with BCRL (all P< 0.05). Taxane-based regimens (odds ratio [OR] = 4.018, 95% confidence interval [CI]: 1.162–13.890), long-course chemotherapy (OR = 4.887, 95% CI: 1.396–17.116), and the combination of neoadjuvant and adjuvant chemotherapy (OR = 4.50, 95% CI: 1.14–17.762) were significantly associated BCRL (all P< 0.05).

Conclusion

Chemotherapy was associated with BCRL. Specifically, this association was observed with taxane-based regimens, long-course chemotherapy, and the combination of neoadjuvant and adjuvant chemotherapy. These findings highlight potential lymphotoxicity of specific regimens and may inform vigilant monitoring for BCRL in patients receiving such therapies, which could facilitate early intervention.

Schlagwörter

Stichwörter der Autor:innen

breast cancerchemotherapyfactorslymphedemaneoadjuvant chemotherapy

Autor:innen und Institutionen

  • Health Management Center (Preventive Treatment) of Baiyun Hospital, Guangdong Provincial Second Hospital of Traditional Chinese Medicine (Guangdong Provincial Engineering Technology Research Institute of Traditional Chi…
  • Department of Radiology, Guangzhou Red Cross Hospital, Guangzhou, China.

Zitieren

APA

Wang, L., Weng, Y., Wei, W., Bu, J., & Zhang, C. (2026). Impact of chemotherapy on breast cancer−related lymphedema: a retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1787021

Vancouver

Wang L, Weng Y, Wei W, Bu J, Zhang C. Impact of chemotherapy on breast cancer−related lymphedema: a retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1787021

BibTeX
@article{Wang2026,
  author = {Wang, Liqin and Weng, Yuemin and Wei, Weiqi and Bu, Jun and Zhang, Cici},
  title = {Impact of chemotherapy on breast cancer−related lymphedema: a retrospective study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1787021}
}
Kostenlos starten →